Breast Cancer: CTSU E5103 (Hematology Oncology Associates)

CTSU E5103: A Double Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer.


The purpose of this study is to determine if adding a medication by the name of
bevacizumab to the current standard chemotherapy of cancer-reducing medications, namely doxorubicin, cyclophosphamide and paclitaxel, reduces the risk of recurrence (called disease-free survival) compared to standard
chemotherapy alone. Patients eligible for this study include those with breast cancer that has been surgically removed, but has features that could indicate a significant risk of recurrence.  

Bevacizumab has been approved by the FDA (Food and Drug Administration) for use in the chemotherapy treatment of patients with colorectal cancer. The outcome for those patients showed improvement with the use of this drug. In this study, bevacizumab is considered investigational because it has not received FDA approval as yet for use in breast cancer. However, this drug has been extensively studied in previous breast cancer clinical trials. These studies showed improved results in patients whose breast cancer recurred. Based on these results, it is hoped that using this medication or this type of medication earlier in treatment of the disease may lead to better outcomes for this group of patients.


Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Cancer Trials Support Unit
Katy D'Aprile, RN, BSN at 563-355-7733


  • University of Iowa Hospital & Clinics, Cancer Center of the Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office